Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for use in veterinary and human health. The company has established itself as a prominent player in the pharmaceutical industry, specializing primarily in the animal healthcare segment. NGL Fine-Chem Ltd caters to various global companies to custom manufacture high-quality pharmaceuticals with reliability and flexibility.
The registered address of NGL FINE-CHEM LIMITED is 301, E Square Subhash Road, Vile Parle (East), Mumbai, Maharashtra, India - 400057. The current status of NGL FINE-CHEM LIMITED is Active. The company operates manufacturing facilities in New Bombay and has been serving the pharmaceutical industry for over four decades.
NGL Fine Chem Ltd (NGLFCL) primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are extensively used in the animal healthcare industry, and the company has developed a comprehensive product portfolio that serves the global animal healthcare market.
The company boasts approximately 39 APIs (37 Veterinary APIs, 2 Human APIs), around 4 Intermediates, and 12 finished dosage forms, etc., within categories such as Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements. Key molecules in its product range include Diminazene Diaceturate, Homidium Chloride, Isometamidium Chloride, Clorsulon, Nitroxynil, Buparvaquone, Parvaquone, Rivastigmine, and Lumefantrine.
NGL Fine Chem Ltd positions itself as "The Largest Veterinary API Manufacturer from India with an Extensive Portfolio of 30+ APIs and 25+ Years of Manufacturing experience with 4 State of the Art Manufacturing Facilities," underscoring its leadership in the veterinary pharmaceutical space.
NGL Fine Chem Ltd is committed to custom manufacturing high-quality pharmaceuticals with reliability and flexibility, catering to diverse global companies. Its business model is centered around adapting to changing customer demands and offering value-added innovative solutions. This commitment is reflected in consistent service and support to its customers.
The company operates with a strong focus on quality and boasts comprehensive manufacturing capabilities. With 95% in-house manufacturing and backward integration, it aims to maintain cost competitiveness. This vertical integration strategy enables NGL Fine Chem to exert better control over quality parameters and cost structures.
Its professionals possess synthetic chemistry expertise coupled with problem-solving skills, which allows them to achieve safe and simple solutions for custom manufacturing needs. Furthermore, the company's commitment to offering solutions for complete scale-up, process development & process validation, and analytical services helps in delivering high-purity compounds at cost-effective prices.
On a consolidated basis, NGL Fine Chem Ltd reported a profit of ₹0.54 crore on a total income of ₹94.01 crore for the quarter ended March 2025. This marks a significant decline in net profit by 95.62% to ₹0.54 crore in Q4 FY25, compared to ₹12.32 crore in the previous quarter ended March 2024. Sales also declined by 4.80% to ₹94.97 crore in Q4 FY25, against ₹99.76 crore in Q4 FY24.
For the full financial year 2024-25, net profit declined by 48.89% to ₹21.12 crore, as compared to ₹41.32 crore in the previous year (FY24). However, sales rose by 8.73% to ₹368.26 crore in FY25, up from ₹338.69 crore in FY24.
• Q4 FY25 Performance: Net Profit of ₹0.54 crore, Total Income of ₹94.01 crore
• FY25 Performance: Net Profit of ₹21.12 crore, Sales of ₹368.26 crore
• FY24 Performance: Net Profit of ₹41.32 crore, Sales of ₹338.69 crore
• Market Capitalization: ₹649 crore (as of June 2025)
• Promoter Holding: 72.74% (as of March 2025)
• 52-Week Range: High: ₹2,774.40, Low: ₹962.70
NGL Fine Chem Ltd operates in a highly competitive environment within the pharmaceutical industry. The company faces strong competition, which often leads to price cutting among players, limiting its pricing power.
A notable characteristic of NGL Fine Chem Ltd's business model is the absence of long-term contracts with most of its customers. The management has informed investors that, apart from a few exceptions, most customers place orders on a spot basis as and when their needs arise.
NGL Fine Chem Ltd successfully completed the commercialization of Phase 1 of its Capital Expenditure (CapEx) project, which included the establishment of a clean room and associated utilities, during the recent quarter. The company remains committed to completing Phase 2 of the CapEx project within the previously communicated timeframe, with expected contributions from FY27 onwards.
Additionally, NGL Fine Chem has completed an expansion in its subsidiary, Macrotech, which has added new capacities for intermediates. Commercial production from this expansion has already commenced, which is expected to contribute to revenue growth in the coming quarters.
The company is strategically focused on strengthening its global presence, with particular emphasis on expanding its footprint in the US and European markets. While non-regulated markets remain a significant revenue source, establishing a stronger presence in regulated markets is crucial for driving sustainable growth.
NGL Fine Chem is also diversifying into related markets, which offers potential for improved profitability amid limited competition. The company is actively focusing on product diversification to reduce dependence on a few key APIs and has a pipeline of new products it aims to introduce in the coming years.
NGL Fine Chem Ltd has encountered significant challenges in recent quarters, reporting a weak financial performance for the December 2024 quarter, which led to a sharp fall in its share price. Rising expenses coupled with lower revenue have impacted profitability, raising concerns among investors.
The steep drop in profit is primarily attributable to higher costs and subdued revenue growth. Increased raw material prices and operational expenses have contributed to reduced margins, consequently putting pressure on overall earnings.
NGL Fine Chem Ltd remains a significant player in the veterinary pharmaceutical API segment, supported by established manufacturing capabilities and a diverse product portfolio. However, the company continues to navigate challenging market conditions characterized by intense competition and margin pressures. The ongoing expansion projects and strategic focus on regulated markets may provide crucial growth opportunities in the medium to long term.
